The combination of insider buying, an above-consensus initiation, and heavy short interest creates a favorable setup for a contrarian squeeze play, but HC Wainwright's below-average track record tempers conviction. Traders should watch for follow-through from higher-accuracy firms before adding size.
ASND drugs
ASND drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 27 $249.36entry
- T+1 · 3mo ago −0.58%α −0.35% · $247.91
- T+5 · 3mo ago +8.73%α +8.46% · $271.12
- T+20 · 8w ago −9.53%α −9.56% · $225.60
- T+56 · todayOpen
- T+60 · in 3d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
HC Wainwright & Co. initiated coverage on Ascendis Pharma A/S (ASND) at Buy with a price target of $345, implying 31% upside from the current $263.04. The firm has a 43% accuracy rate on 4,591 calls and an average return of 2.4%, placing it below average among covering firms. Consensus is overwhelmingly bullish, 25 of 26 analysts rate the stock Buy, with only one Hold and no Sell. The mean target is $315.17, median $313.81, high $362.26, and low $270.72. HC Wainwright's $345 target sits above both the mean and median, reflecting an above-consensus view. Momentum is constructive with 2 upgrades and 0 downgrades in the past 30 days, though EPS estimates for the current quarter and year have been revised downward over the past week and month. Insider activity is noteworthy, the Chief Business Officer bought $492,654 worth of shares on August 14, a bullish signal that aligns with the initiation. However, several institutions exited positions completely and short interest sits at a high 68.8% of float, creating a potential squeeze but also elevated risk. The bottom line: a historically below-average firm initiating at Buy with an above-consensus target is moderately bullish but not a game-changer on its own.
Impact Score
Consensus & Targets
Consensus is 96% Buy, 12 Strong Buy, 13 Buy, 1 Hold, 0 Sell, 0 Strong Sell from 26 analysts. Direction is heavily bullish, with no bearish or strongly bearish ratings. This initiation reinforces that existing skew.
Current price: $263.04. Mean target: $315.17 (implied +19.8%). Median: $313.81. High: $362.26. Low: $270.72. HC Wainwright's $345 PT is above the mean and median, ranking near the top of the range alongside the high target. Implied upside: +31.2% to this firm's target vs +19.8% to consensus mean.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-09-01 | Wedbush | reiterate | Outperform | $327.00 |
| 2026-08-31 | B of A Securities | maintain | Buy | $304.00 |
| 2026-08-31 | Jefferies | maintain | Buy | $330.00 |
| 2026-08-31 | Stifel | maintain | Buy | $326.00 |
| 2026-08-31 | HC Wainwright & Co. | maintain | Buy | $344.00 |
| 2026-08-27 | HC Wainwright & Co. | initiate | Buy | $345.00 |
| 2026-08-19 | BMO Capital | initiate | Outperform | $319.00 |
| 2026-08-14 | TD Cowen | maintain | Buy | $341.00 |
| 2026-08-14 | RBC Capital | maintain | Outperform | $290.00 |
| 2026-08-14 | Barclays | maintain | Overweight | $329.00 |
30-day analyst activity: 2 upgrades, 0 downgrades. Recent actions include Wedbush reiterating Outperform ($327), B of A maintaining Buy ($304), Jefferies maintaining Buy ($330), Stifel maintaining Buy ($326), and HC Wainwright maintaining Buy ($344) after initiation. EPS revisions trend is negative, current quarter EPS estimate fell 27.8% over 7 days (from $1.317 to $0.95), and current year estimate fell 3.4% (from $11.731 to $11.337). However, 1 revision up in the past 7 days for both current year and next year suggests recent stabilization.
Firm Track Record: HC Wainwright & Co.
HC Wainwright & Co. accuracy: 43% on 4591 calls | avg return: 2.4%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 14 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| RBC Capital | 100% | 3/3 | 5.2% | top tier |
| Wedbush | 100% | 4/4 | 5.8% | top tier |
| UBS | 100% | 2/2 | 2.7% | top tier |
| TD Cowen | 100% | 4/4 | 8.3% | top tier |
| Stifel | 100% | 4/4 | 7% | top tier |
| B of A Securities | 80% | 4/5 | 7.7% | top tier |
| Oppenheimer | 80% | 4/5 | 7.3% | top tier |
| Citigroup | 75% | 3/4 | 7.4% | top tier |
| Evercore ISI Group | 67% | 2/3 | -0.7% | top tier |
| Morgan Stanley | 67% | 2/3 | 6.1% | top tier |
HC Wainwright has a 43% accuracy rate on 4,591 rated calls, below the average for firms covering ASND. Their average return is 2.4%. Top-tier firms by accuracy on ASND include RBC Capital (100%, 3/3), Wedbush (100%, 4/4), TD Cowen (100%, 4/4), and Stifel (100%, 4/4). B of A Securities and Oppenheimer each have 80% (4/5). The worst-performing is Goldman Sachs at 33% (1/3) with a -0.2% avg return. HC Wainwright's record is below most peers covering this name.
Earnings Estimates
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0y | $11.34 | $3.61 to $15.60 | $1.4B | ↑1 ↓0 |
| 0q | $0.95 | $0.68 to $1.09 | $365.7M | ↑0 ↓0 |
| +1y | $8.16 | $6.64 to $8.78 | $2.0B | ↑1 ↓0 |
| +1q | $1.18 | $0.67 to $1.51 | $414.3M | ↑0 ↓0 |
Cross-Platform Signals
Insider trades: Chief Business Officer Bienaimé made two large purchases totaling $492,654 on August 14, a bullish signal that aligns with the initiation. No congressional trades reported. Institutional changes show several notable exits, including Avoro Capital, RA Capital Management, and FRED ALGER MANAGEMENT all exiting positions completely (100% reduction to $0). Short interest is elevated at 68.8% of float (357,768 shares short), which is high and suggests potential squeeze dynamics, but also reflects bearish positioning. The insider buying divergence from institutional exits and high short interest creates a mixed picture, insiders see value while institutions and shorts are negative.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Track record
41 reports on ASND
14 of 19 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 24 of 26 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $271.73 −0.08% settles Feb 12
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $275.39 Now $271.73 −1.33% settles Feb 11
- Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
- Nov 6, 202610d ago 6-K Bullish 6/10 Entry $259.85 Now $271.73 +4.57% settles Feb 5
- Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $271.73 +5.81% settles Feb 4
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $271.73 +7.21% settles Feb 3
- Nov 2, 202614d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $271.73 +8.62% settles Feb 1
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $271.73 +10.53% settles Jan 25
- Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $271.73 +20.63% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers